Ferroptosis-centered Disease Response Information
General Information of the Disease (ID: DIS00085)
Name |
Dry eye disease
|
||||
---|---|---|---|---|---|
ICD |
ICD-11: 9A79
|
Full List of Target(s) of This Ferroptosis-centered Disease
Unspecific Target
In total 1 item(s) under this target | |||||
Experiment 1 Reporting the Ferroptosis-centered Disease Response by This Target | [1] | ||||
Responsed Disease | Dry eye disease [ICD-11: 9A79] | ||||
Responsed Regulator | Aldo-keto reductase family 1 member C1 (AKR1C1) | Suppressor | |||
Pathway Response | Fatty acid metabolism | hsa01212 | |||
Ferroptosis | hsa04216 | ||||
Cell Process | Cell ferroptosis | ||||
In Vitro Model | HCE-2 cells | Normal | Homo sapiens | CVCL_3316 | |
In Vivo Model |
A total of 72 female C57BL/6J mice aged 6 to 8 weeks were purchased from Beijing Vital River Laboratory Animal Technology Co., Ltd. (Beijing, China). The mice were injected subcutaneously with scopolamine hydrobromide (1.5 mg/0.3 mL; Sigma-Aldrich) three times daily for 5 consecutive days. Control mice matched for age and sex were maintained in an environment of 50% to 75% relative humidity.
Click to Show/Hide
|
||||
Response regulation | Excessive oxidative stress-induced ferroptosis participates in dry eye disease (DED) pathogenesis. The expression of AKR1C1 is triggered by NRF2 to decrease ferroptosis-induced cell damage and inflammation in HCECs. | ||||